the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |
RSS Feed
Pharmaceutical
Bone Disease Treatment
Cancer
Clinical Trial
DDS
Diabetes
Drug Discovery
eHealthcare
Feminine Hygiene
Gastrointestinal
Generic Drugs
Hematology
Hepatitis
Hypertension
In Vitro Diagnostics(IVD)
Infection Disease
Mental Disease
Neurodegenerative Disease
Obesity Treatment
OTC Drug
Pain
Pharmaceutical Companies
Prescription Drugs
Renal
Therapeutics / Diagnosis
Vaccines
Veterinary Medicine
Wound Care

* View All Categories
Japanese Korean Chinese
Home > Category > Pharmaceutical >

[Report]

Cancer Vaccine Developments to 2013

Published: 2007/09
Contact 24 hrs/day
Description

Table of Contents
  • EXECUTIVE SUMMARY
  • INTRODUCTION
    • What is a cancer vaccine?
      • Figure 1. Potential advantages of therapeutic vaccines for cancer
    • Prophylactic vaccines
      • Overview
        • Table 1. Infectious agents involved in cancer
      • Limitations
    • Therapeutic vaccines
      • Overview
        • Figure 2. Vaccines in Phase II/III development by vaccine type
      • Ag/adjuvant vaccines
      • Whole cell tumour vaccines
      • Dendritic cell vaccines
      • Viral vectors and DNA vaccines
        • DNA vaccines
        • Vector-based vaccines
      • Idiotype vaccines
    • Antigens
      • Carcinoembryonic antigen
      • Ganglioside molecules
      • Heat shock proteins
      • MART-1
      • MUC1
      • NY-ESO-1
      • Prostate specific antigen
      • Sialyl Tn
      • Telomerase
      • Tyrosinase
    • Adjuvants
      • AS04
      • Bacillus Calmette Guerin
      • Interleukins
      • Granulocyte monocyte-colony stimulating factor
      • Incomplete Freund' s adjuvant
      • Keyhole limpet hemocyanin
      • Montanide ISA-51
      • QS-21
    • Monitoring the immune response
      • Proliferation
      • Peptide-major histocompatibility complex multimers
      • ELIS pot
      • Intracellular cytokine assays
    • Challenges of developing vaccines
      • General challenges
        • Antigen selection
        • Adjuvants
        • Generating the correct immune response
        • Long-term immune memory
      • Cancer-vaccine specific challenges
        • Function of thymus
        • Heterogeneity in immune responses
        • Evasion of immune system
        • Tumour-induced immunosuppression
        • Induction of autoimmunity
      • Product standardisation and characterisation
  • MARKET FUTURE
    • Potential targets
      • Tumour types
        • Figure 3. Vaccines in Phase II/III development by indication
      • Disease incidence
        • Figure 4. US cancer statistics
      • Disease settings
    • Combination therapy
      • Figure 5. Potential combination therapy with cancer vaccines
    • Clinical trial designs
      • Proposed clinical trial design
        • Table 2. Proposed clinical trial designs for cancer vaccines
      • Endpoints
        • Patient selection
        • Survival
        • Other time-to-event endpoints
        • Response rate
        • Endpoint modifications
        • Patient-reported outcomes and quality-of-life endpoints
        • Biologic markers
      • Regulatory challenges
      • Market leaders
        • Figure 6. Vaccines in Phase II/III development by company
        • Figure 7. Factors faced by vaccines from their competitors
      • Cost effectiveness
      • Market growth
        • Potential market size
          • Figure 8. Growth drivers and resistors in the therapeutic cancer vaccine market
        • Competition
      • Cervical cancer vaccines: novel challenges
        • Figure 9. Issues faced by human papillomavirus vaccines
      • HPV vaccines
        • Gardasil
        • Cervarix
      • Vaccination population
        • Australia
        • Canada
        • Europe
          • Belgium
          • France
          • Switzerland
        • US
      • Vaccine cost
        • US Government immunisation schemes
      • European reimbursement
        • Sweden
        • UK
    • Less developed countries
    • Safety issues
    • Screening
    • Future research
  • MAJOR AGREEMENTS
    • The advantage of collaboration
      • Figure 10. The benefits of collaboration
      • Table 3. Agreements that could shape the cancer vaccine market
    • The Biomira and Merck KGaA story
      • Stimuvax
    • The Geron and Merck & Co story
      • GRNVAC 1
    • The GSK and Ludwig Institute for Cancer Research story
      • MA GE-A3
    • The Oxford BioMedica and sanofi-aventis story
      • TroVax
    • The Roche and Transgene story
      • TG4001
    • Terminated agreements: big pharma burns its fingers
      • Table 4. Terminated agreements between biotech companies and big pharma
    • Canvaxin
      • CancerVax and Serono
        • The agreement
        • Why did the agreement end?
    • Melacine
      • Corixa and Schering-Plough
        • The agreement
        • Why did the agreement end?
    • GMK Vaccine
      • Progenics Pharmaceuticals and Bristol-Myers Squibb
        • The agreement
        • Why did the agreement end?
    • Insegia
      • Aphton and sanofi pasteur
        • The agreement
        • Why did the agreement end?
      • Theratope
        • Biomira and Merck KGaA
          • The agreement
          • Why did the agreement end?
  • FAILED CANCER VACCINES
    • Figure 11. Reasons why cancer vaccines may have failed in clinical trials
    • Cancer vaccines that have failed in Phase II /II development
      • Table 5. Major cancer vaccine failures
    • Canvaxin failure leads to CancerVax merger
      • Product history
      • Why did the vaccine fail?
    • GMK Vaccine loses BMS backing following inferior results
      • Product history
      • Why did the vaccine fail?
    • GVAX highlights limits of patient-specific vaccines
      • Product history
      • Why did the vaccine fail?
    • Insegia problems force Aphton' s bankruptcy
      • Product history
      • Why did the vaccine fail?
        • Table 6. Insegia Phase III results showing survival by Ab response
    • Melacine; launched and disappeared
      • Product history
      • Why did the vaccine fail?
    • PANVAC-VF failure forces liquidation of Therion
      • Product history
      • Why did the vaccine fail?
    • Early Reniale data still waiting for confirmation
      • Product history
      • Why did the vaccine fail?
    • Theratope disappointment wards off Merck
      • Product history
      • Why did the vaccine fail?
  • LAUNCHED PRODUCTS
    • Vaccines currently on the market
      • Table 7. Vaccines currently on the market
    • OncoVAX
      • Intracel
      • The market(s)
      • The technology
      • Results to date
    • M-Vax
      • AVAX Technologies
        • The market(s)
        • The technology
        • Results to date
    • Gardasil
      • Sanofi Pasteur MSD
        • The market(s)
        • The technology
        • Results to date
    • Cervarix
      • GlaxoSmithKline
        • The market(s)
        • The technology
        • Results to date
    • Estimated sales
      • Gardasil
        • Sanofi Pasteur MSD (sanofi-aventis' joint venture with Merck & Co)
          • Sales forecasts and assumptions
          • Table 8. Sales forecast for Gardasil
      • Cervarix
        • GlaxoSmithKline
        • Sales forecasts and assumptions
          • Table 9. Sales forecast for Cervarix
  • VACCINES IN DEVELOPMENT
    • Table 10. Who' s developing what in Phase II/III?
    • Key launches
      • Table 11. Key vaccine launches to 2013
      • Figure 12. Key vaccine launches by indication
      • Figure 13. Key vaccine launches by vaccine type
  • BREAST CANCER
    • Overview
      • Figure 14. Development phase breakdown for breast cancer
      • Figure 15. Vaccine type breakdown for breast cancer
    • Why is vaccine therapy being explored for breast cancer?
    • Vaccines in Phase II development
      • Table 12. Vaccines in Phase II development for breast cancer
    • Vaccines in Phase I development
      • Table 13. Vaccines in Phase I development for breast cancer
    • Vaccines of interest
      • AE37
      • dHER2 vaccine
      • NeuVax
  • HAEMATOLOGICAL CANCER
    • Overview
      • Figure 16. Development phase breakdown for haematological cancer
      • Figure 17. Vaccine type breakdown for haematological cancer
    • Why is vaccine therapy being explored for non-Hodgkin' s lymphoma?
    • Why is vaccine therapy being explored for leukaemia?
    • Vaccines in Phase III development
      • Table 14. Vaccines in Phase III development for haematological cancers
    • Vaccines in Phase II development
      • Table 15. Vaccines in Phase II development for haematological cancers
    • Vaccines in Phase I development
      • Table 16. Vaccines in Phase I development for haematological cancers
    • BiovaxID
    • Biovest International (Accentia Biopharmaceuticals)
      • The technology
        • Figure 18. The process involved in manufacturing BiovaxID
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Agreements
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • FavId
      • Favrille
        • The technology
          • Figure 19. The process involved in manufacturing FavId
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Agreements
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • MyVax
      • Genitope
        • The technology
          • Figure 20. The process involved in manufacturing MyVax
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • PR1 vaccine
      • The Vaccine Company
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • Other vaccines of interest
      • Oncophage
  • LUNG CANCER
    • Overview
      • Figure 21. Development phase breakdown for lung cancer
      • Figure 22. Vaccine type breakdown for lung cancer
    • Why is vaccine therapy being explored for lung cancer?
    • Vaccines in Phase II development
      • Table 17. Vaccines in Phase III development for lung cancer
    • Vaccines in Phase II development
      • Table 18. Vaccines in Phase II development for lung cancer
    • Vaccines in Phase I development
      • Table 19. Vaccines in Phase I development for lung cancer
    • Lucanix
      • NovaRx
        • The technology
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Agreements
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
  • MAGE-A3
    • GlaxoSmithKline
      • The technology
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Agreements
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • Stimuvax
      • Biomira/Merck KGaA
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • Other vaccines of interest
      • IDM -2101
      • IN GN 225
  • GENITO-URINARY CANCER
    • Overview
      • Figure 23. Development phase breakdown for genito-urinary cancer
      • Figure 24. Vaccine type breakdown for genito-urinary cancer
    • Why is vaccine therapy being explored for prostate cancer?
    • Why is vaccine therapy being explored for renal cell carcinoma?
    • Vaccines in Phase II development
      • Table 20. Vaccines in Phase III development for genito-urinary cancers
    • Vaccines in Phase II development
      • Table 21. Vaccines in Phase II development for genito-urinary cancers
    • Vaccines in Phase I development
    • Table 22. Vaccines in Phase I development for genito-urinary cancers
  • DCVax-Prostate
    • Northwest Biotherapeutics
      • The technology
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • GVAX vaccine
      • Cell Genesys
        • The technology
        • Pivotal trials
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • Oncophage
      • Antigenics
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
  • Provenge
    • Dendreon
      • The technology
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • TroVax
      • Oxford BioMedica/sanofi-aventis
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
      • Other vaccines of interest
        • GRNVAC 1
        • Onyvax-P
        • Reniale
  • GYNAECOLOGICAL CANCER
    • Overview
      • Figure 25. Development phase breakdown for gynaecological cancer
      • Figure 26. Vaccine type breakdown for gynaecological cancer
    • Why is vaccine therapy being explored for ovarian cancer?
    • Vaccines in Phase II development
      • Table 23. Vaccines in Phase III development for gynaecological cancers
    • Vaccines in Phase II development
      • Table 24. Vaccines in Phase II development for gynaecological cancers
    • Vaccines in Phase I development
      • Table 25. Vaccines in Phase I development for gynaecological cancers
    • Amolimogene
      • MGI Pharma
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • TG4001
      • Transgene/Roche
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
      • Other vaccines of interest
        • CV ac
        • HspE7
  • GASTROINTESTINAL CANCER
    • Overview
      • Figure 27. Development phase breakdown for gastrointestinal cancer
      • Figure 28. Vaccine type breakdown for gastrointestinal cancer
    • Why is vaccine therapy being explored for pancreatic cancer?
    • Why is vaccine therapy being explored for colorectal cancer?
    • Vaccines in Phase III development
      • Table 26. Vaccines in Phase III development for gastrointestinal cancers
    • Vaccines in Phase II development
      • Table 27. Vaccines in Phase II development for gastrointestinal cancers
    • Vaccines in Phase I development
      • Table 28. Vaccines in Phase I development for gastrointestinal cancers
    • GV1001
      • Pharmexa
        • The technology
        • Pivotal trials
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • OncoVAX
      • Intracel
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • TroVax
      • Oxford BioMedica/sanofi-aventis
        • The technology
        • Other important trials
        • Results to date
          • Phase II results of TroVax plus CT in CRC
          • Phase II results of TroVax adjuvant therapy in CRC
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
      • Other vaccines of interest
        • Avicine
        • Gastrimmune
        • Oncophage
  • BRAIN CANCER
    • Overview
      • Figure 29. Development phase breakdown for brain cancer
      • Figure 30. Vaccine type breakdown for brain cancer
    • Why is vaccine therapy being explored for brain cancer?
    • Vaccines in Phase II development
      • Table 29. Vaccines in Phase II development for brain cancer
    • Vaccines in Phase I development
      • Table 30. Vaccines in Phase I development for brain cancer
    • CDX-110
      • Celldex Therapeutics
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • DCVax-Brain
    • Northwest Biotherapeutics
      • The technology
      • Pivotal trial
      • Other important trials
      • Results to date
      • Next major event/milestone
      • Market size
      • Competitors
      • Analysis
        • Strengths
        • Weaknesses
    • Other vaccines of interest
      • Oncophage
  • MELANOMA/SARCOMA
    • Overview
      • Figure 31. Development phase breakdown for melanoma/sarcoma
      • Figure 32. Vaccine type breakdown for melanoma/sarcoma
    • Why is vaccine therapy being explored for melanoma?
    • Vaccines in Phase II development
      • Table 31. Vaccines in Phase III development for melanoma/sarcoma
    • Vaccines in Phase II development
      • Table 32. Vaccines in Phase II development for melanoma/sarcoma
    • Vaccines in Phase I development
      • Table 33. Vaccines in Phase I development for melanoma/sarcoma
    • Allovectin-7
      • Vical
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • MDX-1379
      • Medarex/Bristol-Myers Squibb
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Agreements
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • M-Vax
      • AVAX Technologies
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • Oncophage
      • Antigenics
        • The technology
        • Pivotal trial
        • Other important trials
        • Results to date
        • Next major event/milestone
        • Market size
        • Competitors
        • Analysis
          • Strengths
          • Weaknesses
    • Other vaccines of interest
      • Uvidem
  • OTHER VACCINES
    • Overview
      • Vaccines in Phase II development
        • Table 34. Vaccines in Phase II development for other cancers
    • Vaccines in Phase I development
      • Table 35. Vaccines in Phase I development for other cancers
  • SOURCES
    • Espicom sources
    • Others
Description
[Report]
Cancer Vaccine Developments to 2013
Published: 2007/09
Published by : Espicom Business Intelligence Espicom Business Intelligence

Price:
US $ 2,650.00 Hard Copy
US $ 2,650.00 PDF by E-mail (Single User License)
US $ 3,525.00 REPORT + Cancer Vaccine Tracker = WEB ACCESS (Single User License)
>
How to Order?
Product Code : ES55740
Related Products :
Related Topics : Cancer
Please inform me when related publications are released
InfoWatch

| Home | FAQ | Contact | E-mail Alert | About The Infoshop | Policies | Links | Site Map |
Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.